Weight-Loss Drugs: Miracle Cure's Dark Side

GLP-1 weight-loss drugs, such as Wegovy and Mounjaro, are facing increased scrutiny due to emerging side effects. New research indicates over 1.6 million adults in England, Wales, and Scotland used these medications between early 2024 and early 2025. Despite their proven benefits in weight loss and reducing heart attack risk, a rise in emergency room visits for vomiting and dehydration has been noted.

More concerning are links to gallbladder disease and acute pancreatitis. The MHRA updated guidance after a spike in reported fatalities linked to pancreatitis, with 19 deaths reported between 2007 and October 2025. Gallbladder removal surgeries on the NHS increased by nearly 15% in the past year, a rise doctors attribute to GLP-1 use and subsequent gallstone formation.

Patients are also reporting vision loss, leading to lawsuits against manufacturers. These issues, often rare, may only become apparent when drugs are used widely. Concerns also extend to potential impacts on mental health, with some studies suggesting increased risks of depression and anxiety, although evidence remains mixed.

While drugmakers maintain their products have existing warnings and defend against allegations, experts stress the importance of proper medical supervision. The benefits of GLP-1s are significant for certain patients, but careful assessment is crucial to ensure benefits outweigh potential risks.